| Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. | |
| | |
MedLine Citation:
|
PMID: 20372806 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Multiple myeloma (MM) is an incurable disease of malignant plasma cells. Recent therapeutic advancements have resulted in improved response rates, however, there is no improvement in overall survival, therefore, new therapeutics are needed. Since the transferrin receptor is upregulated on the surface of MM cells, we previously developed an antibody fusion protein consisting of an IgG3 specific for the human transferrin receptor 1 (TfR1, CD71) genetically fused to avidin at its carboxy-terminus (ch128.1Av). We have previously shown that ch128.1Av exhibits intrinsic cytotoxicity against certain malignant B-cells by disrupting the cycling of the TfR and decreasing TfR cell surface expression resulting in lethal iron starvation. In addition, ch128.1Av can sensitize malignant cells to apoptosis induced by gambogic acid, a herbal drug used in Chinese medicine. In this study, we hypothesized that ch128.1Av may also sensitize drug-resistant malignant B-cells to chemotherapeutic agents by inhibiting key survival pathways. In this study we show that ch128.1Av sensitizes malignant B-cells to apoptosis induced by cisplatin (CDDP). The sensitization by ch128.1Av resulted in the inhibition of the constitutively activated Akt and NF-kappaB survival/antiapoptotic pathways and downstream decreased expression of antiapoptotic gene products such as BclxL and survivin. The direct role of the inhibition of the Akt and NF-kappaB pathways by ch128.1Av in CDDP-mediated cytotoxicity was demonstrated by the use of specific chemical inhibitors and siRNA which mimicked the effects of ch128.1Av. Overall, this study provides evidence of the therapeutic potential of ch128.1Av as a chemo-sensitizing agent in drug-resistant tumor cells. |
| | |
Authors:
|
Eriko Suzuki; Tracy R Daniels; Gustavo Helguera; Manuel L Penichet; Kazuo Umezawa; Benjamin Bonavida |
Related Documents
:
|
9175716 - Comet assay studies on the activation of two diaziridinylbenzoquinones in k562 cells. 10966416 - Effects of high pressure on survival and metabolic activity of lactobacillus plantarum ... 1741766 - The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl... 20673976 - Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine sero... 19118126 - Eternal youth, the fate of developing arabidopsis leaves upon rhodococcus fascians infe... 17147996 - Biology of langerhans cells and langerhans cell histiocytosis. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: International journal of oncology Volume: 36 ISSN: 1791-2423 ISO Abbreviation: Int. J. Oncol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-07 Completed Date: 2010-11-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9306042 Medline TA: Int J Oncol Country: Greece |
Other Details:
|
Languages: eng Pagination: 1299-307 Citation Subset: IM |
Affiliation:
|
Department of Urology, School of Medicine, Keio University, Shinjuku-ku, Tokyo 165-8582, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies
/
chemistry* Apoptosis* Avidin / chemistry* B-Lymphocytes / pathology* Cisplatin / pharmacology* Humans Immunoglobulin G / chemistry Medicine, Chinese Traditional Membrane Potential, Mitochondrial Multiple Myeloma / metabolism NF-kappa B / metabolism* Proto-Oncogene Proteins c-akt / metabolism* Receptors, Transferrin / chemistry Recombinant Fusion Proteins / chemistry* Xanthones / chemistry |
| Grant Support | |
ID/Acronym/Agency:
|
CA107023-02S1/CA/NCI NIH HHS; CA57152-13S1/CA/NCI NIH HHS; K01CA138559/CA/NCI NIH HHS; R01CA107023/CA/NCI NIH HHS; T32-CA009120/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies; 0/Immunoglobulin G; 0/NF-kappa B; 0/Receptors, Transferrin; 0/Recombinant Fusion Proteins; 0/Xanthones; 1405-69-2/Avidin; 15663-27-1/Cisplatin; 2752-65-0/gambogic acid; EC 2.7.11.1/Proto-Oncogene Proteins c-akt |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dimeric Le(a) (Le(a)-on-Le(a)) status of beta-haptoglobin in sera of colon cancer, chronic inflammat...
Next Document: Fatty acid synthesis is a therapeutic target in human liposarcoma.